Roche Holding AG
Roche Holding AG (RHHVF) Financial Performance & Income Statement Overview
Explore the financials of Roche Holding AG (RHHVF), including yearly and quarterly data on income, cash flow, and balance sheets.
Roche Holding AG (RHHVF) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Roche Holding AG RHHVF financial performance.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $30.65B | $30.76B | $28.94B | $14.91B |
| Cost of Revenue | $8.45B | $7.47B | $8.28B | $3.99B |
| Gross Profit | $22.20B | $23.28B | $20.66B | $10.92B |
| Gross Profit Ratio | $0.72 | $0.76 | $0.71 | $0.73 |
| R&D Expenses | $6.77B | $6.27B | $6.94B | $3.64B |
| SG&A Expenses | $7.25B | $6.26B | $6.71B | $3.49B |
| Operating Expenses | $14.16B | $12.64B | $13.77B | $8.32B |
| Total Costs & Expenses | -$22.61B | $20.28B | $22.05B | $12.31B |
| Interest Income | $0.00 | $0.00 | $0.00 | $147.00M |
| Interest Expense | $623.00M | $625.00M | $423.00M | $0.00 |
| Depreciation & Amortization | $1.77B | $1.65B | $1.72B | $775.00M |
| EBITDA | $5.98B | $10.53B | $8.62B | $4.34B |
| EBITDA Ratio | $0.20 | $0.34 | $0.30 | $0.29 |
| Operating Income | $8.04B | $10.85B | $6.89B | $3.56B |
| Operating Income Ratio | $0.26 | $0.35 | $0.24 | $0.24 |
| Other Income/Expenses (Net) | -$4.45B | -$2.60B | $1.36B | -$1.11B |
| Income Before Tax | $3.59B | $8.25B | $4.92B | $2.45B |
| Income Before Tax Ratio | $0.12 | $0.27 | $0.17 | $0.16 |
| Income Tax Expense | $1.08B | $1.53B | $110.00M | $55.00M |
| Net Income | $2.02B | $6.26B | $4.36B | $2.18B |
| Net Income Ratio | $0.07 | $0.20 | $0.15 | $0.15 |
| EPS | $2.54 | $7.83 | $5.47 | $2.72 |
| Diluted EPS | $2.52 | $7.78 | $5.42 | $2.71 |
| Weighted Avg Shares Outstanding | $795.40M | $799.00M | $797.24M | $801.65M |
| Weighted Avg Shares Outstanding (Diluted) | $802.00M | $804.00M | $804.00M | $804.00M |
Over the last four quarters, Roche Holding AG's revenue moved from $14.91B in Q3 2023 to $30.65B in Q4 2024. Operating income in Q4 2024 was $8.04B, with a strong operating margin of 26%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Roche Holding AG remained robust at $5.98B, reflecting operational efficiency. Net income dropped to $2.02B, with an EPS of $2.54. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan